An Observational Clinical Study Plan on the Effects of Radiotherapy on the Immune System of Patients With Malignant Tumors.

Launched by GUANGZHOU FIRST PEOPLE'S HOSPITAL · Jan 1, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how radiotherapy (a type of cancer treatment that uses high-energy rays to kill cancer cells) affects the immune system of patients with certain types of malignant tumors, such as breast, lung, and colorectal cancers. Specifically, the study will measure changes in different types of immune cells in the blood before and after patients receive radiotherapy. The goal is to see if these changes in immune cells are related to how well the treatment works for the patient.

To participate in this study, you need to be over 18 years old and have a diagnosis of one of the specified cancers that has not spread to other parts of the body. You should be in good health overall, without serious complications or infections, and willing to undergo blood tests. Participants will receive guidance throughout the trial and will need to give their consent before starting. This research could help improve understanding of how radiotherapy interacts with the immune system, which may lead to better treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Over 18 years old, diagnosed with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, head and neck cancer and requiring radiotherapy, and the above malignant tumors have not metastasized.
• • 2. Complete inspection information.
• • 3. No other serious complications.
• • 4. No infectious diseases.
• • 5. Able and willing to take blood tests.
• • 6. All researchers gave informed consent and signed an informed consent form, which complied with the requirements of the Medical Ethics Committee.
• Exclusion Criteria:
• • 1. People with mental illness.
• • 2. People with autoimmune system diseases.
• • 3. Those combined with serious diseases of other organs.
• • 4. Those with severe alcoholism and drug abuse.
• • 5. Research subjects who voluntarily withdraw from the study.